论文部分内容阅读
近年来,人们越来越认识到抗血小板治疗是急性冠状动脉综合征(ACS)治疗的重要组成部分,替罗非班是一种非肽类GPⅡb/Ⅲa受体拮抗剂,它通过阻断血小板聚集的最后共同通路而有效抑制血小板聚集和血栓形成。本文综述替罗非班在老年ACS经皮冠状动脉介入治疗中的应用现状。
In recent years, it is increasingly recognized that antiplatelet therapy is an important part of the treatment of acute coronary syndrome (ACS). Tirofiban is a non-peptide GP IIb / IIIa receptor antagonist that blocks platelet Aggregation of the last common pathway and effective inhibition of platelet aggregation and thrombosis. This article reviews the current status of tirofiban in percutaneous coronary intervention in elderly ACS.